Lakefront Biotherapeutics (LKFT) Inventory Average (2015 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Inventory Average for 9 consecutive years, with $23.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Inventory Average fell 50.75% year-over-year to $23.4 million; the TTM figure through Mar 2026 stood at $23.4 million (down 50.75% YoY), while the FY2025 annual figure was $40.4 million, down 39.77% from the prior year.
• Inventory Average retreated to $23.4 million in Q1 2026 per LKFT's latest filing, from $26.5 million in the prior quarter.
• Across five years, Inventory Average topped out at $83.6 million in Q1 2024 and bottomed at $22.1 million in Q1 2022.
• Historically, Inventory Average has averaged $46.3 million across 5 years, with a median of $43.5 million in 2025.
• Annual changes were most pronounced in 2023 — Inventory Average jumped 148.0% — and 2025, when it tumbled 58.16%.
• Lakefront Biotherapeutics' Inventory Average stood at $22.1 million in 2022, then surged by 217.18% to $70.1 million in 2023, then fell by 9.58% to $63.4 million in 2024, then sank by 58.16% to $26.5 million in 2025, then fell by 11.53% to $23.4 million in 2026.
• Business Quant data shows LKFT's Inventory Average at $23.4 million in Q1 2026, $26.5 million in Q4 2025, and $32.5 million in Q3 2025.